MY126132A - Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases - Google Patents

Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases

Info

Publication number: MY126132A
Authority: MY; Malaysia
Prior art keywords: signal transduction; tyrosine kinases; aminoquinazolines; inhibit signal; transduction mediated
Prior art date: 2000-08-26

Application number

MYPI20013985A

Other languages

English (en)

Inventor

Frank Dr Himmelsbach

Elke Dr Langkopf

Birgit Dr Jung

Stefan Dr Blech

Flavia Dr Solca

Original Assignee

Boehringer Ingelheim Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-26

Filing date

2001-08-24

Publication date

2006-09-29

2001-08-24 Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma

2006-09-29 Publication of MY126132A publication Critical patent/MY126132A/en

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Oncology (AREA)
Immunology (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

MYPI20013985A 2000-08-26 2001-08-24 Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases MY126132A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE10042058A DE10042058A1 (de)	2000-08-26	2000-08-26	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung

Publications (1)

Publication Number	Publication Date
MY126132A true MY126132A (en)	2006-09-29

Family

ID=7653945

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MYPI20013985A MY126132A (en)	2000-08-26	2001-08-24	Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases

Country Status (30)

Country	Link
EP (1)	EP1315705A1 (pl)
JP (1)	JP4834282B2 (pl)
KR (1)	KR100862873B1 (pl)
CN (1)	CN100404517C (pl)
AR (1)	AR033562A1 (pl)
AU (2)	AU8769401A (pl)
BG (1)	BG107559A (pl)
BR (1)	BR0113519A (pl)
CA (1)	CA2417897C (pl)
CZ (1)	CZ302567B6 (pl)
DE (1)	DE10042058A1 (pl)
EA (1)	EA005679B1 (pl)
EC (1)	ECSP034464A (pl)
EE (1)	EE05269B1 (pl)
HR (1)	HRP20030138A2 (pl)
HU (1)	HUP0300819A3 (pl)
IL (2)	IL154602A0 (pl)
ME (1)	MEP58708A (pl)
MX (1)	MXPA03001483A (pl)
MY (1)	MY126132A (pl)
NO (1)	NO324866B1 (pl)
NZ (1)	NZ524668A (pl)
PL (1)	PL360248A1 (pl)
RS (1)	RS52279B (pl)
SK (1)	SK287747B6 (pl)
TW (1)	TWI294422B (pl)
UA (1)	UA73004C2 (pl)
UY (1)	UY26903A1 (pl)
WO (1)	WO2002018351A1 (pl)
ZA (1)	ZA200300991B (pl)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HK1044769B (zh)	1999-06-21	2005-02-25	贝林格尔英格海姆法玛两合公司	雙環雜環化合物，含有該化合物的藥物組合物，該化合物的用途及其製備方法
DE10042059A1 (de) *	2000-08-26	2002-03-07	Boehringer Ingelheim Pharma	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US7019012B2 (en)	2000-12-20	2006-03-28	Boehringer Ingelheim International Pharma Gmbh & Co. Kg	Quinazoline derivatives and pharmaceutical compositions containing them
TWI324597B (en)	2002-03-28	2010-05-11	Astrazeneca Ab	Quinazoline derivatives
JP4776882B2 (ja) *	2002-03-30	2011-09-21	ベーリンガーインゲルハイムファルマゲゼルシャフトミットベシュレンクテルハフツングウントコンパニーコマンディトゲゼルシャフト	二環式複素環化合物、これらの化合物を含む医薬組成物、それらの使用及びそれらの調製方法
US6924285B2 (en)	2002-03-30	2005-08-02	Boehringer Ingelheim Pharma Gmbh & Co.	Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
DE10214412A1 (de) *	2002-03-30	2003-10-09	Boehringer Ingelheim Pharma	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US7576074B2 (en)	2002-07-15	2009-08-18	Rice Kenneth D	Receptor-type kinase modulators and methods of use
DE10326186A1 (de) *	2003-06-06	2004-12-23	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10334226A1 (de) *	2003-07-28	2005-02-17	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
GB0317665D0 (en)	2003-07-29	2003-09-03	Astrazeneca Ab	Qinazoline derivatives
ATE395346T1 (de)	2003-09-16	2008-05-15	Astrazeneca Ab	Chinazolinderivate als tyrosinkinaseinhibitoren
ES2279441T3 (es)	2003-09-19	2007-08-16	Astrazeneca Ab	Derivados de quinazolina.
EP2210607B1 (en)	2003-09-26	2011-08-17	Exelixis Inc.	N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
DE10345875A1 (de) *	2003-09-30	2005-04-21	Boehringer Ingelheim Pharma	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Vewendung und Verfahren zu ihrer Herstellung
US7456189B2 (en)	2003-09-30	2008-11-25	Boehringer Ingelheim International Gmbh	Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
DE10350717A1 (de) *	2003-10-30	2005-06-02	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
US20060035893A1 (en)	2004-08-07	2006-02-16	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es)	2004-12-24	2006-10-06	Boehringer Ingelheim Int	Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
KR20070107151A (ko)	2005-02-26	2007-11-06	아스트라제네카 아베	티로신 키나제 억제제로서의 퀴나졸린 유도체
KR100673775B1 (ko) *	2005-04-08	2007-01-24	엘지전자 주식회사	냉장고용 홈바
CA2619037A1 (en) *	2005-08-22	2007-03-01	Boehringer Ingelheim International Gmbh	Bicyclic heterocycles medicaments comprising said compounds use and method for production thereof
JP5688877B2 (ja)	2005-11-11	2015-03-25	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	癌疾患の治療用キナゾリン誘導体
US20090306105A1 (en) *	2006-03-09	2009-12-10	Boehringer Ingelheim International Gmbh	Bicyclic heterocycles, medicaments containing these compounds, their use and process for preparing them
AU2007299080B2 (en)	2006-09-18	2013-04-18	Boehringer Ingelheim International Gmbh	Method for treating cancer harboring EGFR mutations
EP1921070A1 (de)	2006-11-10	2008-05-14	Boehringer Ingelheim Pharma GmbH & Co. KG	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
AU2008212999A1 (en)	2007-02-06	2008-08-14	Boehringer Ingelheim International Gmbh	Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
US8497369B2 (en)	2008-02-07	2013-07-30	Boehringer Ingelheim International Gmbh	Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
JP5739802B2 (ja)	2008-05-13	2015-06-24	アストラゼネカアクチボラグ	４−（３−クロロ−２−フルオロアニリノ）−７−メトキシ−６−｛［１−（ｎ−メチルカルバモイルメチル）ピペリジン−４−イル］オキシ｝キナゾリンのフマル酸塩
EP2313397B1 (de)	2008-08-08	2016-04-20	Boehringer Ingelheim International GmbH	Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
NZ779754A (en)	2009-01-16	2023-04-28	Exelixis Inc	Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
PT2451445T (pt)	2009-07-06	2019-07-10	Boehringer Ingelheim Int	Processo para secagem de bibw2992, dos seus sais e de formulações farmacêuticas sólidas compreendendo este ingrediente ativo
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
KR101317809B1 (ko)	2011-06-07	2013-10-16	한미약품 주식회사	암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
KR20140096571A (ko)	2013-01-28	2014-08-06	한미약품 주식회사	1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
EP2964638B1 (en)	2013-03-06	2017-08-09	Astrazeneca AB	Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
US9242965B2 (en)	2013-12-31	2016-01-26	Boehringer Ingelheim International Gmbh	Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
KR20160138084A (ko) *	2014-04-04	2016-12-02	하. 룬드벡 아크티에셀스카브	Pde1 저해제인 할로겐화된 퀴나졸린-thf-아민
US20170176028A1 (en)	2015-12-18	2017-06-22	Lg Electronics Inc.	Air conditioner
KR102771603B1 (ko)	2016-11-17	2025-02-24	더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템	Egfr 또는 her2 엑손 20 돌연변이를 갖는 암 세포에 대한 항종양 활성을 갖는 화합물
CN112321814B (zh) *	2020-12-30	2021-03-23	广州初曲科技有限公司	一种吉非替尼艾地苯醌轭合物的制备及用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9508538D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
GB9624482D0 (en) *	1995-12-18	1997-01-15	Zeneca Phaema S A	Chemical compounds
DE69720965T2 (de) *	1996-02-13	2004-02-05	Astrazeneca Ab	Chinazolinderivate und deren verwendung als vegf hemmer
GB9603095D0 (en) *	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline derivatives
NZ331191A (en) *	1996-03-05	2000-03-27	Zeneca Ltd	4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
EA001595B1 (ru) *	1996-04-12	2001-06-25	Варнер-Ламберт Компани	Необратимые ингибиторы тирозинкиназ
GB9718972D0 (en) *	1996-09-25	1997-11-12	Zeneca Ltd	Chemical compounds
DE19911509A1 (de) *	1999-03-15	2000-09-21	Boehringer Ingelheim Pharma	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung

2000
- 2000-08-26 DE DE10042058A patent/DE10042058A1/de not_active Ceased
2001
- 2001-08-18 RS YU14003A patent/RS52279B/sr unknown
- 2001-08-18 CZ CZ20030870A patent/CZ302567B6/cs not_active IP Right Cessation
- 2001-08-18 NZ NZ524668A patent/NZ524668A/en not_active IP Right Cessation
- 2001-08-18 EA EA200300219A patent/EA005679B1/ru not_active IP Right Cessation
- 2001-08-18 MX MXPA03001483A patent/MXPA03001483A/es active IP Right Grant
- 2001-08-18 CA CA002417897A patent/CA2417897C/en not_active Expired - Fee Related
- 2001-08-18 KR KR1020037002744A patent/KR100862873B1/ko not_active Expired - Fee Related
- 2001-08-18 ME MEP-587/08A patent/MEP58708A/xx unknown
- 2001-08-18 UA UA2003032533A patent/UA73004C2/uk unknown
- 2001-08-18 BR BR0113519-8A patent/BR0113519A/pt not_active Application Discontinuation
- 2001-08-18 SK SK231-2003A patent/SK287747B6/sk not_active IP Right Cessation
- 2001-08-18 EP EP01967285A patent/EP1315705A1/de not_active Ceased
- 2001-08-18 AU AU8769401A patent/AU8769401A/xx active Pending
- 2001-08-18 IL IL15460201A patent/IL154602A0/xx unknown
- 2001-08-18 CN CNB01814635XA patent/CN100404517C/zh not_active Expired - Fee Related
- 2001-08-18 AU AU2001287694A patent/AU2001287694B2/en not_active Ceased
- 2001-08-18 JP JP2002523469A patent/JP4834282B2/ja not_active Expired - Fee Related
- 2001-08-18 HR HR20030138A patent/HRP20030138A2/hr not_active Application Discontinuation
- 2001-08-18 WO PCT/EP2001/009532 patent/WO2002018351A1/de not_active Ceased
- 2001-08-18 EE EEP200300077A patent/EE05269B1/xx not_active IP Right Cessation
- 2001-08-18 HU HU0300819A patent/HUP0300819A3/hu unknown
- 2001-08-18 PL PL36024801A patent/PL360248A1/pl not_active Application Discontinuation
- 2001-08-23 UY UY26903A patent/UY26903A1/es not_active Application Discontinuation
- 2001-08-24 TW TW090120905A patent/TWI294422B/zh not_active IP Right Cessation
- 2001-08-24 AR ARP010104041A patent/AR033562A1/es unknown
- 2001-08-24 MY MYPI20013985A patent/MY126132A/en unknown
2003
- 2003-02-03 EC EC2003004464A patent/ECSP034464A/es unknown
- 2003-02-05 ZA ZA200300991A patent/ZA200300991B/en unknown
- 2003-02-14 BG BG107559A patent/BG107559A/bg unknown
- 2003-02-24 IL IL154602A patent/IL154602A/en not_active IP Right Cessation
- 2003-02-25 NO NO20030870A patent/NO324866B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
EE200300077A (et)	2004-12-15
MXPA03001483A (es)	2003-06-06
IL154602A (en)	2008-07-08
CN1449390A (zh)	2003-10-15
HK1057557A1 (zh)	2004-04-08
UA73004C2 (uk)	2005-05-16
EE05269B1 (et)	2010-02-15
KR100862873B1 (ko)	2008-10-15
CA2417897C (en)	2009-03-31
JP2004507529A (ja)	2004-03-11
BR0113519A (pt)	2003-07-01
HRP20030138A2 (en)	2005-04-30
YU14003A (sh)	2006-01-16
IL154602A0 (en)	2003-09-17
EA005679B1 (ru)	2005-04-28
ECSP034464A (es)	2003-03-31
NZ524668A (en)	2006-06-30
MEP58708A (en)	2011-05-10
BG107559A (bg)	2003-10-31
NO20030870D0 (no)	2003-02-25
AU8769401A (en)	2002-03-13
SK2312003A3 (en)	2003-10-07
SK287747B6 (sk)	2011-08-04
NO324866B1 (no)	2007-12-17
HUP0300819A3 (en)	2008-03-28
NO20030870L (no)	2003-02-25
HUP0300819A2 (hu)	2003-09-29
JP4834282B2 (ja)	2011-12-14
ZA200300991B (en)	2004-04-16
DE10042058A1 (de)	2002-03-07
CN100404517C (zh)	2008-07-23
UY26903A1 (es)	2002-03-22
AR033562A1 (es)	2003-12-26
PL360248A1 (pl)	2004-09-06
CZ302567B6 (cs)	2011-07-13
CA2417897A1 (en)	2003-01-30
RS52279B (sr)	2012-10-31
EP1315705A1 (de)	2003-06-04
KR20030024914A (ko)	2003-03-26
AU2001287694B2 (en)	2007-09-06
TWI294422B (en)	2008-03-11
WO2002018351A1 (de)	2002-03-07
EA200300219A1 (ru)	2003-08-28

Publication	Publication Date	Title
MY126132A (en)	2006-09-29	Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
MXPA04003668A (es)	2004-07-22	Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
CY1107054T1 (el)	2012-10-24	Ενωσεις διτοσυλικου αλατος κιναζολινης
WO2002069945A3 (de)	2003-01-30	Neue arzneimittelkompositionen auf der basis von anticholinergika und pde-iv-inhibitoren
BG105765A (bg)	2002-03-29	4-амино-хиназолинови и хинолинови производни с инхибиращо действие върху сигнална трансдукция, медиирана от тирозинкинази
WO2003000695A8 (en)	2004-03-11	Pyrrolopyrimidines as protein kinase inhibitors
EA200200008A1 (ru)	2002-06-27	Бициклические гетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения
TW200510325A (en)	2005-03-16	2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
WO2005062972A3 (en)	2005-10-13	Treatment of cancer with novel anti-il 13 monoclonal antibodies
PL351125A1 (en)	2003-03-24	Derivatives of 4,5-diaryl-3(2)-furanone as inhibitors of cykoxygenease-2
GEP20063868B (en)	2006-07-10	Combination therapy for the treatment of cancer
AP2003002929A0 (en)	2003-12-31	Pyrrolopyrimidines as protein kinase inhibitors
DE60312736D1 (de)	2007-05-03	1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
IL173916A0 (en)	2006-07-05	Thienopyrazoles
IL153680A0 (en)	2003-07-06	Aplidine derivatives and methods for the preparation thereof
MXPA05008780A (es)	2005-10-18	Heterociclos biciclicos, medicamentos que contienen estos compuestos, su utilizacion y preocedimientos para su preparacion.
CO5660287A2 (es)	2006-07-31	Derivados de tetrahidrocarbazol y su uso farmaceutico
MXPA04005809A (es)	2004-09-13	Inhibidores de proteinas quinasas.
MXPA04003910A (es)	2004-07-23	Uso de irbesartan para la preparacion de medicamentos que son utiles para la prevencion o tratamiento de hipertension pulmonar.
WO2003072537A3 (en)	2003-12-18	Selective protein tyrosine phosphatatase inhibitors
PT1255538E (pt)	2004-03-31	Utilizacao do acido 2-metil-tiazolidin-2,4-dicarboxilico e/ou sais compativeis fisiologicamente para tratamento e/ou prevencao de cancros
TW200504051A (en)	2005-02-01	Novel acridine derivatives and their use as medicaments
MXPA02012165A (es)	2003-04-25	Terapia combinada contra tumores que comprende derivados de acriloil-distamicina sustituida, taxanos y/o antimetabolitos.
EA200500865A1 (ru)	2005-12-29	Синергетическая комбинация, включающая рофлумиласт и r,r-формотерол
ZA200405290B (en)	2005-06-17	Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase (serine/threonine kinase) inhibitors.